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TyraminePurpose: Why do anesthetics not activate excitatory ligand-gated ion channels such as 5-HT3 receptors in con-
trast to inhibitory ligand-gated ion channels? This study examines the actions of structural closely-related
5-HT derivatives and 5-HT constituent parts on 5-HT3A receptors with the aim of ﬁnding simpler if not minimal
agonists and thus determining requirements for successful agonist action. Experimental approach: Responses to
5-HT derivatives of human 5-HT3A receptors stably expressed in HEK 293 cells have been examined with the
patch-clamp technique in the outside-out conﬁguration combinedwith a fast solution exchange system. Results:
Phenol, pyrrole and alkyl amines, constituents of 5-HT, even at high concentrations, cannot activate 5-HT3A
receptors but they can inhibit them. To date, tyramines are the smallest known agonists. However, an aromatic
ring is not required for activation as acetylcholine is also an agonist of similar strength. Conclusion: Simultaneous
interactions of adequate strength at two separate subsiteswithin the 5-HT binding domain appear to be essential
for successful agonist function. Anesthetics either fail to achieve this or the activation they produce is so weak
that it is masked by a comparatively very strong inhibition.
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Why do anesthetics not activate excitatory ligand-gated ion chan-
nels such as nicotinic acetylcholine receptors and 5-HT3 receptors,
whereas many anesthetics directly activate inhibitory ligand-gated ion
channels such as GABAA receptor channels or glycine receptor channels
[1,2]? This is surprising as these four ion channel families belong to the
same Cys-loop ligand-gated ion channel superfamily but the selection
of substances as anesthetics that inhibit rather than activate 5-HT3
receptors is consistent with the clinical use of speciﬁc 5-HT3 receptor
antagonists such as ondansetron to treat anesthetic-related emesis.
This is part of a comparative study series exploring molecular
actions of anesthetics and anesthetic related drugs on ion channels,
here on 5-HT3A receptors as prototypes of ligand-gated ion channels
[3–7]. 5-HT3A receptors constitute the only class of serotonergic recep-
tors that form ion channels [8,9]. Being homopentameric receptors
they provide a useful model for the study of molecular drug action
because of their unambiguous stoichiometry [9].
Application of the agonist 5-hydroxytryptamine (5-HT) to 5-HT3A
receptors induces currents activating with time constants of the ordergy and Intensive CareMedicine,
5, D-53127 Bonn, Germany.
iboom), barann@freenet.de
thringroeneveld@msn.com
n).
l rights reserved.of 5–10 ms, which desensitize within a few 100 ms. The kinetics of
conformational changes are relatively slow, permitting the kinetics of
drug action to be studied in detail when using the patch-clamp tech-
nique in the outside-out conﬁguration combined with a fast solution
exchange system [4]. The kinetics of activation are slower than that ob-
served for other Cys-loop ligand-gated ion channels such asGABAA recep-
tors or nicotinic acetylcholine receptors and could suggest differences in
agonist action itself.
Previously, we found that all anesthetics and anesthetic-like sub-
stances studied suppress 5-HT3A receptors while a few drugs such as
some phenol derivatives, in addition to suppression, also have some po-
tentiating action [7]. Altogether, their actions are complex, affecting both
the amplitudes and the kinetics of 5-HT-induced currents. Underlying
mechanisms appear to involve both polar and nonpolar actions. Yet
none of the anesthetics or anesthetic-like substances studied thus far
have been able to activate currents through 5-HT3A receptors in the
absence of 5-HT.
This observation leads to thequestionwhat dominimal agonists of the
5-HT3A receptor look like and how do they compare with anesthetic-like
substances? Since agonists of 5-HT3 receptors are chemically much less
diverse than those activating GABAA receptors, the endogenous agonist
5-hydroxytryptamine (5-HT) and its fragments seems like a good starting
point for approaching this question. The functional groups of 5-HT are the
phenolic hydroxyl-group, the NH-group in pyrrole, the aromatic ben-
zene ring system fused to the pyrrole ring as well as an NH2-group in
ethylamine [10]. Which of these constituent groups are essential for
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within the 5-HT3A binding domain have been proposed and located
within the receptor molecule. Interactions include hydrogen bonding,
cation-π and other aromatic interactions as well as hydrophobic inter-
actions [10].
This study examines the actions of close 5-HT derivatives as well
as of its constituent parts on 5-HT3A receptors with the aim of ﬁnding
simpler if not minimal agonists and thus determining requirements
for successful agonist actions.
2. Methods
2.1. Cell culture
Human embryonic kidney-293 cells stably transfected with human
5-HT3A receptors were grown as mono-layers on culture plates (NUNC,
Wiesbaden, Germany) in DMEM Nutrient Mix F12 medium containing
10% heat-inactivated fetal calf serum, penicillin (100 IU ml−1),
streptomycin (100 μg ml−1), geneticine (750 μg ml−1) and gluta-
mine (292 μg ml−1) [4]. The cells were cultured at 37 °C in a humid-
iﬁed atmosphere (5% CO2) and afterwards transferred to 35-mm
Petri dishes (NUNC). The cells were ready for electrophysiological
experiments 7–11 days after transfer.
2.2. Drugs and solutions
5-HT (serotonin creatinine sulfate complex) and tryptamine
hydrochloride as well as 5-hydroxyindole, indole, pyrrole (98%),
propylamine, 1-pentylamine (99%) nonylamine, m- and p-tyramine
hydrochloride (99%), tryptophan (99.5%), and indoleacetic acid
(98%) were obtained from Sigma-Aldrich Corporation (Taufkirchen,
Germany). Acetylcholine cloride were purchased from Sigma
Aldrich Corporation (Steinheim, Germany), and ondansetron from
Glaxo (Bad Oldesloe, Germany). 5-hydroxyindole was prepared
daily from ethanol stock (1 M) by dilution (e.g. 1:10.000 resulting
in 100 μM) in extracellular buffer and stirring for 1 hour in glass
bottles.
The highest resulting ethanol concentration at the highest
5-hydroxyindole concentration was 27.5 mM; it had no effect on
5-HT control currents. Ethanol concentrations were proportionally
lower at lower drug concentrations. All other substances used
were soluble in the extracellular buffer without any further
vehicle.
The pH-value of propylamine-, pentylamine-, nonylamine- or
tyramine-containing solutions was corrected to 7.45.
2.3. Electrophysiology
Currents through the 5-HT3A receptor were measured with the
patch-clamp technique on excised outside-out patches. Before starting
patch-clamp recordings, the culture medium was replaced by ‘extracel-
lular’ solution of the following composition (mM): NaCl 150; KCl 5.6;
CaCl2 1.8; MgCI2 1.0; HEPES 10; D-glucose 20; pH 7.4. The extracellular
solution used for superfusion contained no D-glucose. Patch pipettes
with resistances of 2–6 MΩ were manufactured from borosilicate glass
capillaries (Kwik-FilTM, World Precision Instruments Inc., USA) using a
pipette puller (List L/M-3P-A, List Electronic, Darmstadt, Germany).
They were ﬁlled with intracellular solution composed of (mM): KCl
140, EGTA 10, MgCl2 5, HEPES 10, pH 7.4. Experiments were performed
at room temperature (18–22 °C). For current measurements we used a
patch-clamp ampliﬁer (EPC-7, List Electronic, Darmstadt, Germany) in
combination with an external low pass ﬁlter set at 1 kHz (either Fre-
quency Devices, MA, USA or LPBF-48DG, NPI Electronic GmbH, Tamm,
Germany). Data were digitally recorded at a sampling rate of 2 kHz
with a Digidata 1200 (Axon Instruments, Foster City, CA, USA) interface
and protocols of the current responses were recorded with Clampex 6software (Axon). 500 ms before 5-HT exposure, themembrane potential
was hyperpolarized from 0 to−100 mV. These conditions were chosen
to optimize the stability of the excised patches and the reproducibility of
results.2.4. Drug application modes
Amultitube rapid perfusion systemwith an exchange rate (solution
exchange) below 2 ms (RSC 200, Biologic, France) was used. The drug
application system was equipped with 5 or 9 separate tubes with
inert materials like Teﬂon tubing and glass to avoid losses of lipophilic
drugs.
When an outside-out patch was excised from a smooth, angularly
shaped cell, extracellular solutionwas applied for a period of 60 s before
starting the measurements. Between each application the patch was
‘washed out’ for at least 60 s with extracellular solution to allow the
receptors to recover from desensitization. The only exception was the
experiment about recovery from desensitization; here wash-out time
differed from 5 s to 50 s.
Each experimental run with the 5-tube or 9-tube conﬁguration
consisted of two or more control currents (30 μM 5-HT only) and
drug applications (30 μM 5-HT and drug), usually alternating between
control and drug. To compensate for rundown effects, the currents
under control conditions and the currents during drug exposure were
averaged, respectively, before further analysis.
The 9-tube conﬁguration allowed the application of three different
drug concentrations to the same patch. An experimental run generally
followed the sequence: control, drug 1, control, drug 2, control, drug
3, control, drug 1, … and was repeated as long as the patch lasted,
always starting with the lowest drug concentration.
In each conﬁguration two different protocols of drug application
were chosen:
1. Equilibrium application: continuous exposure to the drug 60 s
before and during the application of 5-HT;
2. Open channel application: no drug application prior to the 5-HT
pulse, only simultaneous application of drug and 5-HT.2.5. Data analysis
Analysiswas performedwith pClamp8 (Axon Instruments Inc., Foster
City, CA, USA). Graph Pad Prism 3.03 software (GraphPad Software, Inc.,
CA, USA) was used for the creation of graphics.
Whenever possible, the time courses of 5-HT-induced currents were
ﬁtted simultaneously for the rising phase (activation) and decay (possibly
a mixture of desensitization, deactivation and current block) with a
bi-exponential function (pClamp 8, Axon Instruments Inc.), yielding the
time constants τrise and τdecay, respectively. Rarely did they have to be
ﬁtted separately for the activation or decay phases, using a single expo-
nential function respectively.
The concentration–response curves for inhibition were ﬁtted to the
Hill-Equation i(c) = [1 / (1 + cn / IC50n )], i is the remaining peak cur-
rent as a fraction of the maximal (control) current, c is the inhibitory
drug concentration, n is the Hill coefﬁcient, and IC50 is the drug concen-
tration causing a half-maximal effect. The concentration–response
curves for activation were ﬁtted by 1–i(c), where c is the agonist
concentration.
The results are reported as means ± standard deviations (SD). Dif-
ferences between single data pointswere tested for signiﬁcancewith ei-
ther paired or unpaired t-tests (Microsoft Excel and GraphPad Prism
3.03). Differences were considered signiﬁcant when p values for the re-
spective test were less than 0.05. IC50 values and their 95% conﬁdence
intervals for concentration–response curves were obtained from curve
ﬁts with GraphPad Prism 3.03.
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Whole cell measurements had already shown [11] that the
hydroxyl group is not essential for activation as the removal of the
hydroxyl group from 5-HT ( ) still results in
an agonist (tryptamine) though of lesser potency. These observations
are conﬁrmed in our excised outside-out experiments which allow us
to characterize the actions of tryptamine in more detail (Fig. 1). TheA B
C
E
D
Fig. 1. Actions of tryptamine. A: Original traces of 5-HT (30 μM)-induced currents under con
(grey). Tryptamine activated 5-HT3A receptors (n = 5). B: tryptamine (grey) showed an ac
currents (black). EC50 of tryptamine was found to be signiﬁcant larger than that of 5-HT
10 mM; 5-HT: n = 4–30). C: Concentration–response curves for the rise and decay time c
tryptamine time constants were shifted to lower concentrations by about 1.75 log units
pattern of slowing down at higher concentrations (n = 5–7). D: Recovery from desensitiz
was ten times faster for tryptamine (n = 3–5). E: Original trace of a current induced by a com
than the control current induced by 5-HT (30 μM) alone (black) (n = 7) (SD, * = p b 0.05).maximal peak amplitude was only 27% of 5-HT-induced currents
and occurred at similar concentrations (300 μM tryptamine) as for
5-HT, although the EC50 for tryptamine was found at larger concen-
trations (greater than 100 μM) compared with 5-HT (7 μM (Fig. 1B),
3.8 μM [12]).
Similar to 5-HT-activated currents, time constants both of current
activation and of current desensitization decrease with increasing
tryptamine concentrations; however, they appear to be shifted along
the concentration axis (Fig. 1C). At a concentration equivalent to thattrol conditions (black) as well as current of tryptamine (300 μM) in the absence of 5-HT
tivation efﬁcacy which was around 27 ± 13% (p = 0.00005) of 5-HT (30 μM) induced
by 1.75 log units (tryptamine: n = 4–6 for each concentration point except n = 2 at
onstants of currents evoked by different concentrations of 5-HT or tryptamine. When
, they became comparable to those of 5-HT-induced currents and showed a similar
ation after an application of either 5-HT (30 μM) or tryptamine (1 mM). 50% recovery
bination of tryptamine (1 mM) and 5-HT (30 μM) (grey), which is signiﬁcantly smaller
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activation) they are rather similar and then show the same trend with
increasing concentration as the time constants for 5-HT (Fig. 1C).
50%-recovery from desensitization after an application of either
5-HT or tryptamine was ten times faster for tryptamine than for
5-HT (Fig. 1D).
When applied together, tryptamine inhibited 5-HT activated currents,
the degree of inhibition depending on whether it had already been given
prior (60 s) to the application of 5-HT (complete inhibition at 0.1 mM
tryptamine, data not shown) or only together with 5-HT. In the latter
case, a clear acceleration of current offset can be observed (Fig. 1E).
The addition of a COOH-group to the ethylamine residue of tyramine
( ) results in tryptophan. This molecule fails to
activate the 5-HT3A receptor (data not shown; three experiments each
at 100 μM and 300 μM). Turning tryptophol into indoleacetic acid by
making the hydroxyl group acidic ( ) also caused
the loss of the ability to activate the 5-HT3A receptor (data not shown;
three experiments each at 300 μM and 3 mM).
When ethylamine instead of the hydroxyl group is removed from
the 5-HT molecule ( ), the remaining molecule
(5-hydroxyindole) is no longer able to activate 5-HT3A receptors
(not shown, 1 mM, n = 3). Thus, actions of 5-hydroxyindole could
only be observed in the presence of 5-HT. In contrast to the effects
of tryptamine, 5-hydroxyindole potentiated rather than inhibited
5-HT-induced currents (Fig. 2A) and slowed rather than accelerated
their offset (Fig. 2C).
When pyrrole is removed from the 5-hydroxyindole molecule
( ), the remaining molecule (phenol) still did
not activate (0.1–3 mM) but it potentiated 5-HT-induced currents
more potently and slowed their offset more strongly than did 5-
hydroxyindole (Fig. 2A). In equilibrium application it had been previ-
ously shown to suppress the peak amplitudes in a concentration-
dependent manner (IC50 1.6 mM; [7]).
When instead of pyrrole the hydroxyl group is removed from the
5-hydroxyindole molecule ( ), the remaining in-
dole also did not activate but like phenol it potentiated 5-HT-induced
currents more strongly and slowed their offset more strongly than did
5-hydroxyindole (Fig. 2A). In equilibrium application it suppressed
the peak amplitudes (IC50 greater than 3 mM).
If now the pyrrole group is removed from indole( ),
the molecule benzene is obtained which neither activated nor potenti-
ated [7].
When benzene instead of pyrrole is retained from the indole mole-
cule ( ), there is also no activation. However, depending
on its concentration, pyrrole can either slow or accelerate 5-HT-induced
current decay. In the presence of 10 mM pyrrole, desensitization in
5-HT-induced currents was slowed in the open-channel-mode. By con-
trast, a signiﬁcant acceleration of current decay was observed at the
concentration of 30 mM pyrrole in the same application mode (71 ±
3.6%, p = 0.0005). In the open channel application there was some
potentiation of current amplitude, while in equilibrium application pyr-
role caused current inhibition with an IC50 = 17 mM (Fig. 2B).
Since the presence of ethylamine appears to be important for
direct activation, the effects of alkylamineswere studied by themselves.
Propylamine( )was not able to activate the receptor in the
absence of 5-HT (1 mM: n = 3). Also longer-chain amines such as
pentylamine ( , 10 mM: n = 5) and nonylamine
( , 1 mM: n = 3; 100 μM: n = 3) did not causeactivation of the receptor. All three amines inhibited the 5-HT3A
receptor, the IC50 for propylamine in the equilibrium application was
5.6 mM; the more lipophilic amines pentylamine and nonylamine
inhibit even more potently (data not shown) as expected [3].
If the alkylamines showed activation too weak to be experimentally
detected in our set-up, the effectmay become larger in the presence of a
hydroxyl group, similar to the potency increase between tryptamine
and 5-hydroxtryptamine. Therefore, aminoalkanols were also investi-
gated. However, neither 5-amino-pentanol ( ) nor
6-amino-hexanol ( ) activated the receptor
detectably (data not shown).
Next, a derivative of amino-alkanol with the ethylamine attached to
an aromatic compound (yielding tyramine), rather than a straight
chain alkane (yielding 8-amino-octanol) was investigated. p-Tyramine
( ) and m-tyramine ( ) were characterized, they differ
only in the position of the hydroxyl group. While 3 mM p-tyramine
induced a currentwith a peak amplitude of 2.7% ± 0.004 of themaximal
peak amplitude of 30 μM 5-HT, 3 mM m-tyramine-induced current
reached a peak amplitude of 14% ± 0.02 of themaximal peak amplitude
of 30 μM 5-HT (Fig. 3A, B).
However, an aromatic ring system does not appear to be a prerequi-
site for an agonist as acetylcholine ( ) can also weakly activate
5-HT3A receptors (Fig. 4A). The I–V curve of these currents is rectifying
and comparable to that for 5-HT (Fig. 4B). It can be blocked by
ondansetron and return after washout of ondansetron (Fig. 4C, D).
If the concurrent occupancy of several interaction subsites of
the 5-HT3A receptor was required that neither propylamine nor
5-hydroxyindole could achieve by themselves, then this simultaneous
occupancy might be accomplished by giving these two compounds
simultaneously. A concentration range between 3 mM and 10 mM
was chosen for a number of reasons: i) for both 5-HT and tryptamine
maximum activation was observed at 300 μM: in order to achieve the
same simultaneous occupancy of several subsites by two different com-
pounds one would expect that each constituent would have to be
administered at a higher concentration than the original compound;
ii) for both 5-HT and tryptamine activation was observable at 3 mM
but would be blocked at concentrations greater than 10 mM (Fig. 1);
iii) propylamine at 3 mM showed substantially less than 50% block of
5-HT-induced currents (IC50 = 5.6 mM in equilibrium application),
while 5-hydroxyindole showed no signiﬁcant block at 3 mM;
iv) 5-hydroxyindole potentiated in the 1 mM range (Fig. 2). However,
the combination of the drugs propylamine and 5-hydroxyindole (both
at 3 mM or both at 10 mM) was not able to activate the receptor
when given alone in the absence of any 5-HT (n = 3/3) (data not
shown).
4. Discussion
What does a minimal agonist at the 5-HT3A receptor look like? The
functional groups of 5-HT are a phenol and a pyrrole (forming an aro-
matic indole ring systems) aswell as an ethylamine group [10]. Positions
where these groups may bind to the 5-HT3A binding domain have been
proposed [10,13]; they include three different interaction subsites, inter-
actions taking place with the ethylamine rest (subsite E), with the aro-
matic ring structure including the secondary amine in the pyrrole ring
(subsite P), and with the phenolic hydroxyl group (subsite H), respec-
tively. In Table 1 probable subsites are proposed where the functional
groups of the various 5-HT derivatives are expected to be localized dur-
ing activation. Which of these 5-HT constituent groups are essential for
agonist function at the 5-HT3A receptor?
Table 1 demonstrates that there is no single functional group that is
identical for all agonists. Additionally, Table 1 shows that occupancy of a
single subsite obviously does not lead to agonist activation as neither
the alkylamine (subsite E), nor pyrrole (subsite P) or phenol (subsite H)
by themselves are able to activate 5-HT3A receptors. In fact, all active
AB
C
Fig. 2. Potentiation of 5-HT3A receptors. A: Original traces of 5-HT (30 μM)-induced currents under control conditions (black) and after the application of 5-HT (30 μM) together with the
substance (grey). The currents show potentiation induced by 5-OH-indole (1 mM), indole (1 mM), pyrrole (10 mM) and phenol (1 mM) in the open-channel-application (n = 3–13).
B: Concentration–response curves for the peak amplitude (in % of the peak amplitude of currents induced by 30 μM5-HT) of currents evoked by 30 μM5-HTwith different concentrations
of pyrrole. Depending on the concentration the peak amplitudewas inhibited in equilibrium. Aweak potentiation could be observed in the open-channel-application at a concentration of
10 mM pyrrole (SD, * = p b 0.05, n = 4–5). C: Concentration–response curves for the decay time constants (in % of the control current induced by 30 μM 5-HT) of currents evoked by
different concentrations of 5-HT with (triangle) and without (square) the additional application of 1 mM 5-hydroxyindole (open channel-application). It can be observed that
5-hydroxyindole slowed current decay at all tested 5-HT concentrations (SD, * = p b 0.05 for points at the same concentration, n = 5–13; continuous line chosen for visualization
purposes only, no mechanism implied).
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AB
Fig. 3. Tyramine activated 5-HT3A receptors. A: Original traces of p-tyramine (3 mM) (light grey) and m-tyramine (3 mM) (dark grey) induced currents and 5-HT (30 μM)-induced
currents under control conditions (black). Both substances activated the 5-HT3A receptors (n = 5). B: Proportion of the peak current of p-tyramine (3 mM) and m-tyramine
(3 mM) to the peak current of 5-HT (30 μM). m-Tyramine activated 5-HT3A receptors more potent than p-tyramine (14 ± 1.8% vs. 2.7 ± 0.4%) (m-tyramine: n = 13,
p-tyramine: n = 31).
2569M.F. Meiboom et al. / Biochimica et Biophysica Acta 1828 (2013) 2564–2573agonists listed in Table 1 have in common that they possess two func-
tional groups that during activation are presumably localized at subsite
E and at subsite P, respectively. Apparently, subsite H does not have to
be occupied.
This is consistent with tryptamine lacking the hydroxyl group being
a partial agonist (Fig. 1B). However, the hydroxyl group is important be-
cause it turns the partial agonist tryptamine into the full agonist 5-HT,
possibly by stabilizing certain protein conformations that allow the
two amines to simultaneously stay longer in contact with subsites E
and P, respectively. Supporting this hypothesis, recovery from desensi-
tization is much faster for tryptamine than for 5-HT (Fig. 1D).
Replacing the hydroxyl with a methoxy group yields 5-
methoxytryptaminewhich no longer acts as an agonist, possibly because
it is excluded from subsite H due to the size of its methoxy group as
argued by Bower et al. [8]. However, this exclusion also must imply a
re-orientation of the molecule such that its two amines can no longer
simultaneously occupy subsites E and P; otherwise activation should be
observed as for tryptamine. While the methoxy group may be excluded
from subsite H, it needs not be excluded from subsite E which seems to
be large enough to even accommodate the trimethylammonium group
of quaternary 5-HTQ [11]. Thus, simultaneous occupancy of subsites E
(methoxy) and P (indole) may be the reason why 5-methoxyindole is
able to activate the receptor [14]. Other partial agonists also function
without an ethylamine group such as 3-(2-hydroxyethyl) indole
(Table 1) as well as the class of biguanides [10,14].
Why then does 5-hydroxyindole not activate the receptor since
the smaller hydroxyl group should also ﬁt into subsite E? The reason
could be that the smaller and more polar hydroxyl group may ﬁndpartners to interact with at competing subsites other than E, subsites
that do not lead to activation but perhaps to inhibition instead.
5-Hydroxyindole inhibits muchmore potently (40 times) than indole,
and possibly 5-methoxyindole. This inhibition, therefore, which is
pronounced at low concentrations already, may mask a weak activation
caused by 5-hydroxyindole at higher concentrations. This may also ex-
plain why the combination of propylamine and 5-hydroxyindole does
not activate 5-HT3A receptors. Thus while the combined molecules con-
tain all necessary functional groups required for activation, the concen-
trations for each of the two molecules required to ensure simultaneous
occupancy of two separate subsites may be so high that inhibition by
one or both of these molecules masks any potential activation. Trypto-
phan (in contrast to tryptamine) and idoleacetic acid (in contrast to
tryptophol) fail to cause direct activation. The additional functional acidic
COOH group may again ﬁnd other competing binding sites causing inhi-
bition or its negative charge may prevent site E to be occupied [13].
As noted above, not all substances containing two appropriately
spaced functional groups, for example, a hydroxyl group linked to
an alkylamine, show agonist activity. Indeed, 5-amino-pentanol or
6-amino-hexanol fails to activate. Not an alcoholic hydroxyl group
but rather a phenolic hydroxyl group in conjunction with ethylamine
(yielding tyramine) was able to activate the receptor. Acetylcholine
proves that no aromatic ring system is required at all for a molecule
to be an agonist at the 5-HT3A receptor (Fig. 4). Apparently the func-
tional groups of successful agonists must not only be able to reach
both subsites E and P simultaneously, but interactions with these
subsites have to be sufﬁciently strong to initiate activation. In partic-
ular clinical intravenous and inhalation anesthetics do not appear to
AB
D
C
Fig. 4. Acetylcholine activated 5-HT3A receptors. A: Original traces of acetylcholine (1 mM) induced currents (grey) and 5-HT (30 μM)-induced currents under control conditions.
Acetylcholine activated 5-HT3A receptors (n = 3) B: Current induced by 1 mM acetylcholine at variable voltage. The I–V curve is also rectifying and comparable to that for 5-HT.
C: Original traces of acetylcholine (1 mM)-induced currents before (black) and after 1 min exposure to ondansetron (1 nM) (grey) and after a wash-out-phase of 6 min after the
application of ondansetron (1 nM) (identical with the last white square in D). The currents induced by acetylcholine were inhibited by ondansetron, a selective 5-HT3 receptor
antagonist. D: Peak amplitudes of sequential current traces induced 1 min after the previous trace by either 30 μM 5-HT or 1 mM acetylcholine while having been exposed during
the preceding minute by either ECS or ECS + 1 nM ondansetron: 5-HT after 1 min ECS (white triangle), acetylcholine after 1 min ECS (white square), acetylcholine after 1 min
ondansetron (grey square) and 5-HT after 1 min ondansetron (black triangle) (same patch as in C). The 5-HT3 receptor selective antagonist ondansetron inhibited
acetylcholine-induced currents as well as 5-HT-induced currents, proving that the current induced by acetylcholine is mediated by 5-HT3 receptors. The inset on the right
shows an enlargement of this ﬁgure for the data with acetylcholine as agonist.
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tional groups that are capable to interact sufﬁciently strongly with
these two sites.
M-tyraminewas about four toﬁve timesmore efﬁcacious in activating
currents through 5-HT3A receptors than its isomer p-tyramine (Fig. 3),
perhaps because the spacing between the nitrogen and the hydroxylgroup of m-tyramine more closely resembles the spacing between the
primary and secondary nitrogen in 5-HT. If so then this would support
the hypothesis that the phenolic hydroxyl group of tyramine is located
near subsite P (rather than at subsite H) when activation takes place.
While these discussions must remain speculative at this point, they
suggest that it is speciﬁc combinations of more than one functional
Table 1
Molecular structures of the different substances, their ability to activate, potentiate or inhibit, and their potential interaction subsites at the 5-HT3A receptor.
Drug Structure Direct activation Potentiation IC50 open channel IC50 equilibrium Subsite E Subsite P Subsite H
5-HT ++ … >30 mM 30.3 nM \NH2 _NH Φ
5-HTQa ++ … … … \N+ _NH Φ
5-MTb o … … … \NH2 − −
\ _NH −
Tryptamine + o b1 mM ≪0.1 mM \NH2 _NH −
HEIc (tryptophol) + … … … \OH _NH −
5-Hydroxy-indole o + >3 mM 0.9 mM − _NH Φ
Φ _NH −
5-MIc + … … … \OCH3 _NH −
Phenold o ++ >3 mM 1.6 mM − − Φ
Indole o + >3 mM 38 mM − _NH −
Benzold o o + 5.7 mM − − −
Pyrrole o + ≥30 mM 17 mM − _NH −
(10 mM)
Propylamine o o >30 mM 5.6 mM \NH2 − −
Pentylamine o o ~2 mM ≪1 mM
Nonylamine o o ~0.1 mM ≪0.1 mM
6-Amino hexanol o … … … \NH2 − \OH
\NH2 \OH −
\OH \NH2 −
5-Amino hexanol o … … … \NH2 − \OH
\NH2 \OH −
\OH \NH2 −
p-Tyramine (+) o ~4 mM b10 mM \NH2 Φ −
(continued on next page)
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Table 1 (continued)
Drug Structure Direct activation Potentiation IC50 open channel IC50 equilibrium Subsite E Subsite P Subsite H
m-Tyramine +/(+) … … … \NH2 Φ −
Dopaminea + … … … \NH2 Φ −
Acetylcholine (+) … … … \N+ _O −
5-Hydroxyindole + o o b10 mM b10 mM
+ Propylamine
Indoleacetic acid o … … … … … …
Tryptophan o … … … … … …
Column 1: compounds that have been characterized in other publications are indicated by superscripts which refer to the respective citation [a: Hooft and Vijverberg (van Hooft and
Vijverberg, 1996); b: Bower et al. (Bower et al., 2008); c: Hu and Peoples (Hu and Peoples, 2008); d: Barann et al. (Barann et al., 2000b)].
Column 3: indicates agonist activity (++: full agonist; +: partial agonist; (+): partial agonist activity near detection limit; o: no agonist activity detectable).
Columns 4, 5 and 6: list the ability of the substance to potentiate (slow the offset) or inhibit 5-HT (30 μM) induced currents in the open-channel-application (column 5) while
column 6 shows their inhibition potency in equilibrium (+: effect present, −: effect absent; … : not determined; ~ estimated).
Columns 7, 8 and 9: suggested interaction subsites at the agonist binding pocket (Barnes et al., 2009).
Subsite E = position near Y234 (ethylamine of 5-HT).
Subsite P = position near Y153 (pyrrole of 5-HT).
Subsite H = position near E123 or F226 (hydroxyl of 5-HT).
The suggested interaction positions of the functional groups (\NH2: primary amine,_NH: secondary amine as in pyrrole, \N+: quaternary amine, \OH: hydroxyl, Φ: phenolic,
\OCH3: methoxy) are indicated. The simplifying assumption is made that when a functional group of a molecule is the same as in 5-HT, it will also occupy the same interaction
position as suggested for 5-HT.
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trast to the nicotinic acetylcholine receptor where a single hydrophobic
cation such as tetramethylammonium can activate the receptor [15].
If not activating directly, howdo these substances and their different
functional groups affect currents through 5-HT3A receptor ion channels?
Considering activation ﬁrst, functional groups that each alone were not
essential for a (partial) agonist action, nevertheless were important in
strengthening agonist action. Thus, the partial agonist tryptamine was
turned in a full agonist through the addition of the hydroxyl group
(Fig. 1). Addition of a hydroxyl group tom-tyramine yields the stronger
partial agonist dopamine [11]. The addition of pyrrole changes
m-tyramine into the full agonist 5-HT. When ethylamine replaces
ethanol in the partial agonist 3-(2-hydroxyethyl)indole [14] it yields
tryptamine which remains a partial agonist, though its desensitization
time constants become faster and more like that of the full agonist
5-HT. The hydroxyl group also inﬂuences desensitization such that,
for example, recovery from desensitization for 5-hydroxytryptamine
(5-HT) is at least ten times slower than for tryptamine.
Turning to potentiation (i.e., increase of current amplitude or
slowing of current decay) next, functional groupsmay have ambivalent
effects. The hydroxyl in phenol caused current potentiation in 5-HT3A
receptors which was absent in benzene [7]. On the other hand, when
the hydroxyl group was added to indole, 5-hydroxyl-indole showed alesser degree of potentiation than indole (Fig. 2). When benzene was
added to pyrrole, the resulting indole showed stronger potentiation
than pyrrole (Fig. 2).
However, inhibition is the dominating action that all the sub-
stances considered here share. Even 5-HT at high concentrations
causes inhibition (Fig. 1B). Alkylamines, benzene, phenol, pyrrole,
indole and 5-hydroxyindole all inhibit 5-HT-induced currents when
given in the equilibrium application, the hydroxyl group turning
phenol in a three to four times more potent inhibitor than benzene
and 5-hydroxyindol into a forty times more potent inhibitor than
indole (for IC50 values see Table 1). Alkylamine appears to interact
more potently with 5-HT3A receptors than suggested by their lipophilic-
ity [3], in agreementwith the expectation that they can show speciﬁc in-
teractions at subsite E. Of interest is also the suggestion that the decline
in the 5-HT concentration–response curve beyond 300 μM (Fig. 1) may
result from the agonist at high concentrations inhibiting the current it
has induced [16]. The inhibitory action is also the reasonwhyhigher con-
centrations could not be used in the experiments where solutions
containing both propylamine and 5-hydroxyindole were investigated
regarding their ability to activate currents through 5-HT3A receptors in
the absence of 5-HT. Though higher concentrations of both propylamine
and 5-hydroxyindole may have insured the adequate simultaneous
occupancy of interaction subsites necessary for receptor activation, the
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Thus simultaneous interaction with the two subsites suggested above
may only be a necessary but not a sufﬁcient condition for a drug to be
able to activate currents through 5-HT3A receptors because additional
and also simultaneous inhibitory action may prevent current ﬂow.
The different functional groups constituting the agonist 5-HT
appear to have several and perhaps simultaneous actions on activation,
potentiation and inhibition. Thismay involve distinct interaction and/or
binding sites on 5-HT3 receptors. For example, evidence has been
reported that potentiation by 5-hydroxyindole involves a site different
from the agonist binding site [17]. This implies that 5-HT itself may be
able to interact with sites other than the agonist site where it causes
activation, as has been suggestedwithin the context of current inhibition
at high agonist concentration (see above). Thus it is also conceivable that
different agonists use a different combination of functional groups at
the interaction subsites when causing activation. In tyramine, the only
amine available for interaction is contained in ethylamine, whereas in
5-methoxyindole or in 3-(2-hydroxyethyl) indole it is the amine in the
pyrrole ring.
In conclusion, we ﬁnd that excitatory 5-HT3 receptors in contrast to
inhibitory receptors such as GABAA receptors can only be activated by
substances that are chemically far less diverse. It appears that all sub-
stances that can activate 5-HT3 receptors are able to interact with sub-
sites E and P of the 5-HT agonist site simultaneously. We propose that
anesthetics and anesthetic-like substances are either not capable of
such interactions of sufﬁcient strength to cause activation or that activa-
tion is so weak that it is completely masked by the comparatively much
more powerful inhibition they cause. The inability for excitatory 5-HT3
receptors to be activated by a wide range of chemical substances
could be an evolutionary adaptation in response to endogenous
anesthetic-like substances [18].Acknowledgements
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